EIGHT VERTICALS.
ONE DISCIPLINE
Rigorous intelligence grounded in clinician access, proprietary data, and operator experience. Here is how we see each market — and where we help clients move.
01 · Diabetes
Diabetes remains the most dynamic competitive arena in healthcare. Automated insulin delivery is maturing, CGM is expanding beyond intensive insulin management toward broader type 2 populations, and GLP-1 therapies are redrawing demand for drugs and devices alike. Our view: the next five years will be decided less by incremental accuracy or algorithm gains than by access — coverage policy, primary-care prescribing, and pharmacy-channel economics.
This is Seagrove's deepest vertical. Clients draw on the GlobeVIEW forecasting workbook spanning device and drug markets across 52 geographies, SeaTRAK quarterly competitive tracking, and five annual research waves across prescribers, patients, payers, and international clinicians. We model share scenarios and coverage shifts, track every launch and earnings season, and bring operator experience from inside one of the industry's landmark device launches.
02 · Oncology
Oncology's pipeline has never been broader — antibody-drug conjugates, bispecifics, radioligands, and an expanding universe of targets — while precision segmentation keeps making each market narrower and more contested. Our view: the traditional syndicated model is failing this space. Most teams already own shelves of generic 200-page reports; what they lack is continuous tracking paired with depth on the questions that are actually theirs.
That conviction shaped GlobeVIEW Oncology Select, our hybrid offering: quarterly competitive intelligence as the foundation, with custom deep-dive reports directed entirely by the client. Those reports follow the model of our flagship tumor-type work — 200-plus pages built from rigorous secondary research, with fifteen-plus company profiles, product outcome deep-dives, and extensive target-level analysis — focused wherever your strategy needs depth most.
03 · Primary Care & Metabolic
Primary care is where modern cardiometabolic medicine converges. Obesity, diabetes, lipids, and hypertension are increasingly managed as one condition cluster, GLP-1 demand is pulling once-specialist decisions into generalist offices, and nurse practitioners and physician assistants write a growing share of prescriptions. Our view: the brands that win this decade will be the ones that understand generalist workflow — not just specialist opinion.
This is the launch vertical for GlobeVIEW Clinical Intelligence, our prescriber-panel platform. Pulse custom studies and Amulet24 memberships are fielded to curated panels of primary care physicians, general internists, NPs, PAs, and obesity-medicine specialists across 49 states — purpose-built to reach the front line where adoption, switching, and treatment-intensification decisions actually happen.
04 · Cardiology & Cardio Renal
Medicine has entered the cardio-kidney-metabolic era. SGLT2 inhibitors, GLP-1s, and novel agents are crossing traditional specialty lines, guidelines are moving faster than practice, and the boundaries between cardiology, nephrology, and primary care are blurring. Our view: the decisive commercial question in this space is no longer efficacy — it's ownership. Which clinician manages the patient, and how referrals and prescribing actually flow, determines who captures the market.
Seagrove helps clients map exactly that. We field Pulse research across cardiology and adjacent cardiometabolic prescribers, build patient-flow and care-pathway models for overlapping indications, and construct forecasts that capture cross-specialty dynamics. Amulet24 members get rapid, contextualized response when trial readouts, label expansions, or guideline updates move the landscape.
05 · Acute Care & Health Systems
Adoption decisions have migrated from individual clinicians to institutions. Value analysis committees, group purchasing, and service-line economics now gate what reaches the bedside, while margin pressure and staffing constraints shape adoption as powerfully as clinical evidence — and care keeps shifting toward outpatient and home settings. Our view: winning the clinician is still necessary, but it is no longer sufficient. You have to win the committee.
Seagrove helps clients see the institution whole. We conduct custom-recruited qualitative and quantitative research with the people who sit in those decisions — service-line leaders, pharmacy and supply-chain stakeholders, committee members — model site-of-care economics and demand shifts, and track how competitors are positioning, contracting, and landing across systems.
06 · Immunology & Inflammation
Immunology holds the largest pipeline outside oncology, with new mechanisms advancing across dermatology, rheumatology, and gastroenterology, franchise brands hopping indications, and biosimilar erosion plus drug-pricing reform reshaping lifecycle economics. Our view: differentiation in this space now happens in sequencing — where a therapy slots into the treatment ladder, and what it takes to displace an entrenched first-line agent — more than in head-to-head efficacy claims.
Seagrove helps clients fight for position on that ladder. Pulse studies probe prescriber sequencing logic, switching triggers, and payer-driven behavior across specialties; our competitive intelligence tracks readouts, launches, and label expansions in near real time; and our forecasting discipline sizes crowded categories honestly. When a competitor's data drops, Amulet24 members have context within 24 hours.
07 · Neuroscience & Behavioral Health
After decades of retrenchment, neuroscience has momentum again: the first disease-modifying therapies in neurodegeneration, genuinely novel mechanisms in depression and schizophrenia, and long-overdue investment in behavioral health access. Our view: in this vertical, infrastructure and access decide commercial outcomes more than clinical data — diagnostic confirmation, specialist capacity, and reimbursement pathways gate adoption long before efficacy debates are settled.
Seagrove helps clients navigate those gates. We field Pulse research among psychiatrists, neurologists, and the primary care clinicians who deliver much of real-world behavioral care, run qualitative work that surfaces adoption barriers candidly, and build uptake models for novel mechanisms where historical analogs are scarce and infrastructure constraints — not demand — set the pace.
08 · Diagnostics
Diagnostics is where modern medicine begins. Companion and molecular testing increasingly determine treatment eligibility, point-of-care and home-based testing are moving diagnosis closer to the patient, and the line between diagnostic and monitoring keeps blurring. Our view — shaped by deep roots in continuous glucose monitoring, the defining diagnostic-monitoring hybrid — is that adoption in this space is won in workflow and coverage, not analytical performance.
Seagrove helps diagnostics clients see the whole adoption chain. We field research among ordering clinicians through our Pulse panels, map where a test genuinely fits in the care pathway, model test volumes under alternative coverage scenarios, and track the competitive moves of platform players — so clients know not just whether their test works, but whether and where it will be used.